CORDIS · 101007205 · H2020
HyShip DEMONSTRATING LIQUID HYDROGEN FOR THE MARITIME SECTOR
Coordinator: WILH WILHELMSEN HOLDING ASA (NO)
The develops and validates approaches to build (3MW) and scale (to 20MW) fuel cell approaches that lower operational cost (capex) and design cost of LH2 PEM operations. We integrate the technical solutions in a larger socio-technical system, in cooperation with linked projects and considerable investments that the project will help generate, with the result of providing what could be the first European maritime supply chain for LH2. This is helped by having the demonstrator as one of two planned sister ships that will connect a new hydrogen production facility with LH2 demand in a series of v…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €8.0M toward a total project budget of €10.8M — a funding rate of 74%, with the remainder covered by the consortium partners. The project runs over approximately 5 years from 2021-01-01 to 2025-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · CH · €89.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the FCH2-IA funding scheme.
- What is the EU contribution?
- The European Commission contributes €8.0M toward a total project budget of €10.8M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-FCH-2020-1.
- Who coordinates the project?
- The project is coordinated by WILH WILHELMSEN HOLDING ASA (NO).
- What is the project timeline?
- The project runs from 2021-01-01 to 2025-12-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101007205.